Want to see VYGR full AI Analyst Report?

Voyager Therapeutics (VYGR) Price & Analysis

1,412 Followers

VYGR Stock Chart & Stats

$3.48

$0.01(0.32%)

At close: Jul 24 4:00 PM EDT

$3.48

$0.01(0.32%)

Day’s Range― - ―

52-Week Range$1.89 - $5.48

Previous CloseN/A

Volume484.46K

Average Volume (3M)663.71K

Market Cap

$126.32M

Enterprise Value$128.15M

Total Cash (Recent Filing)$116.34M

Total Debt (Recent Filing)$32.57M

Price to Earnings (P/E)―

Beta1.51

Next Earnings

Nov 10, 2026

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.81

Shares Outstanding61,617,947

10 Day Avg. Volume891,418

30 Day Avg. Volume663,710

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.18

Price to Sales (P/S)5.71

P/FCF Ratio-1.71

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue3.72

Enterprise Value/Gross Profit3.72

Enterprise Value/Ebitda-1.23

Forecast

1Y Price Target

$13.75

Price Target Upside295.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-1.7

Revenue Forecast (FY)$20.27M

Bulls Say, Bears Say

Bulls Say

Manageable LeverageModerate leverage gives Voyager a less debt-constrained financial structure than a highly leveraged biotech, reducing near-term interest and refinancing pressure. This can preserve some capacity to fund neurological programs, although the benefit depends on stabilizing the company’s capital base.

Demonstrated ProfitabilityVoyager’s 2023 results show that its business has previously converted revenue into meaningful profit, demonstrating potential earnings power under favorable operating or partnership conditions. That history provides a foundation for recovery if future programs and commercial arrangements rebuild revenue.

Neurological Gene-Medicine PlatformSpecialized AAV capsid engineering and central-nervous-system delivery capabilities can support multiple genetic-medicine programs rather than a single asset. This platform orientation may create durable strategic value as Voyager advances therapies for severe neurological diseases.

Bears Say

Sustained Revenue DeclineThe prolonged decline in revenue indicates weakening commercial or partnership-derived business activity rather than a single-quarter fluctuation. Lower receipts reduce internal funding for research and development, making recovery dependent on successfully rebuilding program revenue or other operating income.

Accelerating Cash BurnThe shift from positive operating cash generation to substantial recurring burn materially reduces financial flexibility. Continued outflows can consume resources needed for clinical development and may increase reliance on financing or strategic transactions to sustain the pipeline over the next several quarters.

Losses And Shrinking EquityPersistent losses are eroding the company’s equity cushion, reducing resilience even though debt remains moderate. A smaller capital base limits the ability to absorb further development setbacks and increases the potential importance of external funding if losses continue.

Voyager Therapeutics News

Voyager Therapeutic CEO Alfred Sandrock to depart, Robin Swartz to succeed

Voyager Therapeutics (VYGR) announced that its board of directors has appointed Robin Swartz, currently chief business officer and...

1h ago

VYGR

Voyager Therapeutics advances leadership transition amid Alzheimer’s focus

An announcement from Voyager Therapeutics ( ($VYGR) ) is now available. On October 20, 2026, Voyager Therapeutics appointed...

1h ago

VYGR

Voyager Therapeutics: Buy Rating Reiterated as Alzheimer’s Pipeline Advances; $25 Price Target Maintained

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

2M ago

VYGR

Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist

Voyager Therapeutics Inc. ($VYGR) announced an update on their ongoing clinical study. Voyager Therapeutics Inc. is preparing a...

2M ago

VYGR

Voyager Therapeutics Reaffirmed Buy on Advancing Alzheimer’s Pipeline and 4Q26 Tau Program Catalysts; $8 Price Target Maintained

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from...

2M ago

VYGR

Voyager Therapeutics reports Q2 EPS (40c), consensus (51c)

Reports Q2 revenue $3.17M, consensus $4.56M. “We view tau as a critical disease-modifying target in Alzheimer’s disease, and...

3M ago

VYGR

Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

3M ago

VYGR

Voyager Therapeutics advances tau-silencing gene therapy program

Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and...

3M ago

VYGR

Voyager Therapeutics presents six-month toxicology data for VY1706

Voyager Therapeutics (VYGR) presented six-month good laboratory practice toxicology data for VY1706, the company’s investigational gene therapy targeting...

3M ago

VYGR

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

The latest update is out from Voyager Therapeutics ( ($VYGR) ). On June 9, 2026, Voyager Therapeutics, Inc....

4M ago

VYGR

Voyager Therapeutics announces FDA clearance for VY1706 IND application

Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706,...

5M ago

VYGR

Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy

The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). On June 1, 2026, Voyager Therapeutics, Inc....

5M ago

VYGR

Voyager Therapeutics: Advancing CNS Gene Therapy Pipeline and TRACER Platform Underpin Buy Rating and Unchanged $25 Price Target

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

5M ago

VYGR

Voyager awarded new mission management contract with Exobiosphere

Voyager Technologies and Exobiosphere announced a mission management contract on the International Space Station that marks a concrete...

5M ago

VYGR

VYGR FAQ

What was Voyager Therapeutics’s price range in the past 12 months?

Voyager Therapeutics lowest stock price was $1.89 and its highest was $5.48 in the past 12 months.

What is Voyager Therapeutics’s market cap?

Voyager Therapeutics’s market cap is $126.32M.

When is Voyager Therapeutics’s upcoming earnings report date?

Voyager Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.

How were Voyager Therapeutics’s earnings last quarter?

Voyager Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.084.

Is Voyager Therapeutics overvalued?

According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics pay dividends?

Voyager Therapeutics does not currently pay dividends.

What is Voyager Therapeutics’s EPS estimate?

Voyager Therapeutics’s EPS estimate is -0.42.

How many shares outstanding does Voyager Therapeutics have?

Voyager Therapeutics has 61,617,947 shares outstanding.

What happened to Voyager Therapeutics’s price movement after its last earnings report?

Voyager Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 4.473%.

Which hedge fund is a major shareholder of Voyager Therapeutics?

Currently, no hedge funds are holding shares in VYGR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.92%

Trailing 12-Months

Asset Growth

-38.61%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Voyager Therapeutics

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$13.75

▲(295.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.675,4.392307692307692,6.109615384615385,7.826923076923077,9.544230769230769,11.26153846153846,12.978846153846153,14.696153846153845,16.413461538461537,18.13076923076923,19.848076923076924,21.565384615384616,23.282692307692308,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.675,3.526923076923077,4.378846153846154,5.23076923076923,6.082692307692307,6.934615384615384,7.786538461538461,8.638461538461538,9.490384615384615,10.342307692307692,11.194230769230767,12.046153846153846,12.898076923076921,{"y":13.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.675,3.0846153846153843,3.494230769230769,3.9038461538461537,4.313461538461539,4.723076923076922,5.132692307692308,5.542307692307692,5.951923076923077,6.361538461538461,6.771153846153846,7.18076923076923,7.5903846153846155,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.675,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >